Microba Life Sciences (ASX:MAP) said that preliminary results from an analysis of over 4,600 MetaXplore GI Plus test results show that the test can support clinicians to identify and address underlying gastrointestinal issues that often go undetected by conventional testing, according to a Wednesday Australian bourse filing.
The MetaXploreGI Plus is a comprehensive test for the assessment and management of lower gastrointestinal disorders.
The test revealed findings, such as abnormalities in gut bacteria, signs of infection, or markers of inflammation or insufficiency, in over 70% of cases. In a separate study, 65.5% of the patients reported improvements in the symptoms following clinician-directed recommendations informed by MetaXplore.
The firm's shares fell 9% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.